Home Cart Sign in  
Chemical Structure| 1818314-88-3 Chemical Structure| 1818314-88-3

Structure of BMS-1166
CAS No.: 1818314-88-3

Chemical Structure| 1818314-88-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-1166 can disrupt PD-1/PD-L1 interaction with IC50 value of 1.4nM. It can antagonize the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

Synonyms: BMS-1166

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-1166

CAS No. :1818314-88-3
Formula : C36H33ClN2O7
M.W : 641.11
SMILES Code : O=C(O)[C@@H]1N(CC2=CC(Cl)=C(OCC3=CC=CC(C4=CC=C(OCCO5)C5=C4)=C3C)C=C2OCC6=CC=CC(C#N)=C6)C[C@H](O)C1
Synonyms :
BMS-1166
MDL No. :MFCD31746874
InChI Key :QBXVXKRWOVBUDB-GRKNLSHJSA-N
Pubchem ID :118434635

Safety of BMS-1166

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P301+P312-P302+P352-P304+P340-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PD-1/PD-L1 interaction

    PD-1/PD-L1 interaction, IC50:1.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Jurkat/PD-1 10 μM 17 hours BMS1166 inhibited PD-L1/PD-1 signaling and restored effector T cell function. PMC7567511
Jurkat T-lymphocytes 40.5 µM 48 hours Assessed the toxicity of BMS-1166 on Jurkat T cells, showing low toxicity. PMC5641120
H1975 10 μM 17 hours BMS1166 altered the glycosylation pattern of PD-L1 in H1975 cells. PMC7567511
MDA-MB-231 10 μM 48 hours To evaluate the inhibitory effect of BMS-1166 and BMS-T7 on PD-L1 expression in MDA-MB-231 cells. Results showed that BMS-T7 was more effective than the naked drug in inhibiting PD-L1 expression. PMC11725277
Human pluripotent stem cell-derived macrophages 500 nM or 1 µM around two weeks BMS-1166 reduced the percentage of CD45+CD11B+ macrophages, phenocopying the effect of PD-L1 knockout. PMC10638094
PC9/PD-L1 10 μM 17 hours BMS1166 partially inhibited N-glycosylation of PD-L1 and prevented the transport of under-glycosylated PD-L1 from the endoplasmic reticulum (ER) to the Golgi, leading to accumulation of PD-L1 in the ER. PMC7567511
SW480R cells 1 μM 24 hours Evaluate the inhibitory effect of BMS-1166 on SW480R cell proliferation and migration, results showed that BMS-1166 inhibited cell proliferation and migration. PMC11302559
SW480 cells 0.5 μM 24 hours Evaluate the inhibitory effect of BMS-1166 on SW480 cell proliferation and migration, results showed that BMS-1166 inhibited cell proliferation and migration. PMC11302559

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice A53T-syn transgenic mice In vitro culture 1 μM Single treatment, 48 hours To evaluate the reversal effect of BMS-1166 on T cell suppression induced by A53T-syn sEVs, results showed that BMS-1166 significantly reversed the inhibitory effects of A53T-syn sEVs on cytokine production in CD4+ and CD8+ T cells PMC11246066

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.56mL

0.31mL

0.16mL

7.80mL

1.56mL

0.78mL

15.60mL

3.12mL

1.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories